Xeltis Receives €50 Million to Propel aXess Vascular Conduit Development Xeltis has secured almost €50 million from the European Investment Bank and existing shareholders to enhance its aXess vascular conduit. This investment supports its commercialization and further innovations in medical technology.

Xeltis Receives €50 Million to Propel aXess Vascular Conduit Development #EIB #Netherlands #Xeltis #aXess #Eindhoven

Xeltis prepares for commercial launch after strong aXess trial results - PharmaTimes EU phase 3 data shows major gains in dialysis access performance

#nephrology #Xeltis #aXesstrialresults #aXessclinicaltrial #phase3trial #restorativevascularaccess #vascularaccess #haemodialyisis #primaryendpoint #endstagerenaldisease #haemodiaylisisvascularaccesstreatment #EndogenousTissueRestorationplatform #vascularaccess #dialysispatients
zurl.co/UPkoj

Xeltis Launches Groundbreaking Vascular Access Technology for Hemodialysis Treatment Xeltis has released positive results from the pivotal aXess EU trial, showcasing a revolutionary solution for vascular access in hemodialysis treatment, paving the way for commercialization.

Xeltis Launches Groundbreaking Vascular Access Technology for Hemodialysis Treatment #Xeltis #aXess #Eindhoven #The_Netherlands #Hemodialysis

Xeltis Unveils Promising Results for Xabg: A Potential Game Changer in Coronary Bypass Surgery Xeltis announces positive preliminary results for Xabg, a groundbreaking coronary bypass conduit that may reshape heart surgery by eliminating vein harvesting.

Xeltis Unveils Promising Results for Xabg: A Potential Game Changer in Coronary Bypass Surgery #Netherlands #Xeltis #Eindhoven #Xabg #Coronary_Bypass

#PortfolioNews I Our #portfolio company #Xeltis passes #EIC evaluation for potential €10M funding

🎯Developing regenerative implants to transform vascular surgery through natural tissue regeneration.

👉 buff.ly/rl7BP3W

#vc #innovation #dialysis

Xeltis Secures €10 Million Investment to Transform Vascular Surgery with Groundbreaking Technology Xeltis has passed the evaluation phase for a €10 million investment from the European Innovation Council to enhance its bioresorbable vascular conduits.

Xeltis Secures €10 Million Investment to Transform Vascular Surgery with Groundbreaking Technology #Netherlands #Xeltis #aXess #Eindhoven #EIC

Xeltis Enhances Medical Advisory Board with Renowned Nephrology Experts Xeltis announces the addition of Dr. An De Vriese and Dr. Monnie Wasse to its Medical Advisory Board, enhancing its clinical expertise in nephrology.

Xeltis Enhances Medical Advisory Board with Renowned Nephrology Experts #Netherlands #Xeltis #aXess #Eindhoven #Nephrology

Xeltis Completes Enrolment for aXess Trial and Readies for Market Entry Xeltis has completed patient enrolment for its aXess trial, aiming for a market approval soon. This marks a significant step in transforming vascular access for dialysis patients.

Xeltis Completes Enrolment for aXess Trial and Readies for Market Entry #Netherlands #medical_technology #Xeltis #aXess #Eindhoven